Sugi Predict

Sugi Predict / Compounds / SCHEMBL4499056

SCHEMBL4499056

SCHEMBL4499056

COC(=O)c1cnc(Cl)cc1N

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.56
▸ KDM4E B2RXH2 6/20 0.50
▸ GAA P10253 5/20 0.49
▸ ALDH1A1 P00352 5/20 0.49
▸ HSD17B10 Q99714 3/20 0.49
▸ MAPT P10636 3/20 0.49
▸ GLA P06280 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ CASP1 P29466 1/20 0.49
▸ CASP7 P55210 1/20 0.49
▸ ATM Q13315 1/20 0.49
▸ TSHR P16473 2/20 0.45
▸ CFTR P13569 3/20 0.44
▸ NQO2 P16083 5/20 0.43
▸ ALOX15 P16050 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29977172 1.00 ABL1 (0.56) ABL1KDM4EGAAALDH1A1HSD17B10
SCHEMBL30763395 0.86 KDM4E (0.51) ABL1KDM4EGAAALDH1A1HSD17B10
SCHEMBL3714762 0.86 KDM4E (0.51) ABL1KDM4EGAAALDH1A1HSD17B10
SCHEMBL29416286 0.84 KDM4E (0.49) ABL1KDM4EGAAALDH1A1MAPT
SCHEMBL977733 0.84 KDM4E (0.49) ABL1KDM4EGAAALDH1A1MAPT
SCHEMBL29551416 0.82 KDM4E (0.44) ABL1KDM4EGAAALDH1A1MAPT
SCHEMBL474122 0.82 KDM4E (0.44) ABL1KDM4EGAAALDH1A1MAPT
SCHEMBL2445600 0.82 HSP90AA1 (0.50) KDM4EALDH1A1HSD17B10MAPTHPGD
SCHEMBL29374466 0.82 HSP90AA1 (0.50) KDM4EALDH1A1HSD17B10MAPTHPGD
SCHEMBL27039493 0.82 ATR (0.38) ABL1MAPTALOX15LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 — — US disclosed
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-11-13 — — US disclosed
US-12410183-B2 Sars-cov2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
US-20250270206-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS NNSA 2025-08-28 — — US disclosed
EP-4554938-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 — — EP disclosed
CN-119894879-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-25 — — CN disclosed
CN-119731159-A SARS-CoV2 main proteinase inhibitor 吉利德科学公司 2025-03-28 — — CN disclosed
WO-2025054488-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2025-03-13 — — WO disclosed
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2025-02-06 — — US disclosed
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed
WO-2010057899-A1 CYCLOALKYL AMINO CARBONYL DERIVATIVES AS BRADYKININ-B1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-27 — — WO disclosed
US-7557115-B2 Compounds, compositions, and methods CYTOKINETICS, INC. (US) 2009-07-07 — — US disclosed
EP-1558083-A4 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC (US) 2008-04-16 — — EP disclosed
US-20060264449-A1 Compounds, compositions, and methods CYTOKINETICS, INC. 2006-11-23 — — US disclosed
EP-1558083-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2005-08-03 — — EP disclosed
WO-2004034972-A2 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2004-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE ABL1 1001/4885KDM4E 3744/4885GAA 180/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS ABL1 170/4885KDM4E 2825/4885GAA 2089/4885
US-12410183-B2 Sars-cov2 main protease inhibitors ACE2, TMPRSS2, ACE ABL1 1001/4885KDM4E 3744/4885GAA 180/4885
US-20250270206-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS KRAS, NRAS, HRAS ABL1 115/4885KDM4E 3717/4885GAA 966/4885
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES PSEN1, BRCA1, PSEN2 ABL1 776/4885KDM4E 2930/4885GAA 64/4885
US-20060264449-A1 Compounds, compositions, and methods ALPP, PCNA, MKI67 ABL1 3150/4885KDM4E 1488/4885GAA 314/4885
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES WRN, RECQL, BLM ABL1 3186/4885KDM4E 3487/4885GAA 429/4885
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 ABL1 5/4885KDM4E 1141/4885GAA 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.